Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 4/20 | 0.54 |
| ▸ | GCGR | P47871 | 3/20 | 0.46 |
| ▸ | GIPR | P48546 | 2/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647861 | 0.79 | MEN1 (0.49) | PTGESALOX5 | |
| SCHEMBL4096992 | 0.75 | GCGR (0.78) | GCGRGIPRGLP1RPTGESALOX5 | |
| SCHEMBL219654 | 0.75 | EPHX2 (0.68) | FAAHEPHX2MRGPRX4 | |
| SCHEMBL2648427 | 0.75 | PDK2 (0.46) | GCGRGIPRPDK1 | |
| SCHEMBL1239730 | 0.74 | SERPINE1 (0.90) | SERPINE1GCGRGIPRGLP1RPTGES | |
| SCHEMBL4082151 | 0.74 | GCGR (0.69) | GCGRGIPRGLP1R | |
| SCHEMBL3974584 | 0.73 | MAPT (0.41) | SERPINE1 | |
| Hydrochloric Acid SCHEMBL8086285 | 0.73 | EPHX2 (0.66) | FAAHEPHX2MRGPRX4 | |
| SCHEMBL22721344 | 0.72 | MRGPRX4 (0.70) | MRGPRX4 | |
| SCHEMBL1241400 | 0.72 | SERPINE1 (0.93) | SERPINE1GCGRGIPRGLP1RPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | SERPINE1 578/4885GCGR 2/4885GIPR 3/4885 |
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | SERPINE1 578/4885GCGR 2/4885GIPR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.